Identification and Validation of Novel Diagnostic Biomarkers for Keloid Based on GEO Database

Yeletai Nurzati

Zhu Zhu

Heng Xu

Yixin Zhang

Department of Plastic and
Reconstructive Surgery, Shanghai Ninth
People's Hospital, Shanghai JiaoTong
University School of Medicine, Shanghai,
201100, People's Republic of China

Introduction: Keloid is a pathological scar type, which invades normal surrounding tissue without self-limiting to cause pain, itching, cosmetic disfigurement, etc. Knowledge of the molecular mechanisms underlying keloid remains unclear. This dilemma leads to no biomarker available for diagnosis. Thus, to seek accurate diagnosis, biomarkers are necessary for keloid diagnosis to help control its incidence.

Methods: Gene Expression Omnibus (GEO) database was used to select differentially expressed miRNAs (DE-miRNAs) in GSE113620. miRTarBase miRNA–target tools were used to predict the interactions between miRNAs and their target mRNAs. Target mRNAs that were differentially expressed in keloid were selected by analyzing differentially expressed genes (DEGs) in GSE44270 and GSE92566. PPI network analysis, gene enrichment analysis, cell-specific and tissue-specific expression analyses of DE-target mRNAs were conducted. RT-PCR analysis was conducted to validate our results.

Results: Three novel miRNAs (miR-30b-5p, miR-212-3p, miR-149-5p) and five target mRNAs (*SIX1*, *CCNA2*, *CCNB1*, *FOXM1*, *RUNX2*) were identified as potential biomarkers for keloid patients. Additionally, the potential functions of those miRNAs-mRNAs pathways were analyzed.

Discussion: These findings of keloid-related miRNAs, mRNAs, and miRNA–mRNAs regulatory networks may provide insights into the underlying pathogenesis of keloid and serve as potential biomarkers for keloid diagnosis.

Keywords: diagnostic biomarkers, miRNA–mRNA network, keloids, differentially expressed genes

Introduction

Keloid is excessive fibrosis of the skin that extends beyond the area of injury and does not regress.¹ Keloid can occur in the joints and mouth after several years of severe injury, including burns, chemical injury, wound, and surgical incision.² Keloids on the joints affect the quality of life, physical, mental, and social health.³ Knowledge of the molecular mechanisms underlying keloid remains unclear. This dilemma leads to no biomarker available for diagnosis, and, therefore, result in the diagnosis of keloid in clinical practice is highly dependent on the experience of the clinician. Thus, to seek an effective biomarker may offer an alternative to the current clinical pain point.

MicroRNAs (miRNAs) are evolutionarily conserved short (20–23 nucleotides) noncoding RNAs with no protein-coding potential but can negatively or positively regulate genes.⁴ Previous studies have shown that miRNAs can inhibit gene expression by binding to the 3′-untranslated regions (UTR) of target mRNAs,

Correspondence: Heng Xu; Yixin Zhang
Email xuh1990@gmail.com;
zhangyx1576@163.com

thus inhibiting mRNA translation or promoting mRNA degradation.^{5,6} Several studies have revealed that miRNAs are involved in various biological pathways, such as cell proliferation, apoptosis, cell cycle, differentiation, metabolism, and abnormal expression of miRNAs, which may impair a variety of cell functions, leading to cancer and other diseases.⁷ Several studies have shown that miRNAs are biomarkers for keloid.⁸ Therefore, it is important to reveal the biological function of miRNAs in keloids to analyze the mechanism of fibroblasts in keloids effectively. This study aimed to investigate several potential biomarkers for distinguishing keloid patients from non-keloid patients.

Gene Expression Omnibus (GEO) database was used to identify DE-miRNAs and their target mRNAs differentially expressed in keloid and control groups. A DE-miRNA and differentially expressed target mRNAs (DE-target mRNAs) network was then constructed after a comprehensive analysis. Further, protein–protein interaction (PPI) network analyses, functional enrichment analysis, tissue-specific and cell-specific gene expression analysis were performed. Validation analysis was conducted using RT-PCR experiment. Three potential miRNAs and five target mRNAs were identified as significant predictors of keloid. This study may provide novel diagnostic biomarkers for keloid.

Materials and Methods

Data Source and Identification of DE-miRNAs/DE-mRNAs

MicroRNA expression profile data of GSE113620 were obtained from Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) database, which is based on GPL19117 [miRNA-4] Affymetrix Multispecies miRNA-4 Array. RNA-seq detection and miRNA expression data were analyzed in serial skin biopsies from the same site (baseline and 6 weeks post-injury) of keloid-prone (n=8) and healthy matched control individuals (n=6). Differential expression analysis was conducted in four comparison groups: 1) Keloid-prone subjects vs healthy subjects in baseline, 2) Keloid-prone subjects vs healthy subjects 6 weeks after wounding, 3) Keloid-prone subjects in baseline vs keloid-prone subjects 6 weeks after wounding, and 4) Healthy subjects in baseline vs healthy subjects 6 weeks after wounding. The mRNA expression profile data of GSE44270 and GSE92566 were obtained from the GEO database (which are based on GPL6244 and

GPL570, respectively) to identify common mRNAs between the target mRNA of DE-miRNA and DEGs in GSE44270 and GSE92566. For GSE44270 analysis, keloid scars were excised from patients undergoing scar excision surgery. Normal skin samples were isolated from patients undergoing elective plastic surgery. This study had six experimental groups, including nine cases of keloid fibroblast (KF), nine cases of keloid keratinocyte (KK), four cases of keloid non-lesional fibroblast (NKF), four cases of keloid non-lesional keratinocyte (NKK), three cases of normal fibroblast (CF) and three cases of normal keratinocyte (CK). For GSE92566 analysis, transcriptional profiling was conducted using Affymetrix HGU133 2.0 plus arrays for three groups, including large chronic keloids (n=3), adjacent non-lesional keloid samples (n=3), and a newly formed keloid lesion. The Affymetrix CEL files and the probe annotation files were obtained from the GEO database. Meanwhile, all the samples were preprocessed with background correction. The Bioconductor package (<http://www.bioconductor.org/packages/2.8/bioc/html/affy.html>) (R studio Version 1.1.383) was used to select DE-miRNAs. The $|\log_2FC$ (fold change) >1 and FDR <0.05 were used as the cut-off criteria for selecting DE-miRNAs. “ggplot” package was used for data visualization.

Identification of Target mRNA of DE-miRNAs

Identifying target mRNAs of miRNAs is a necessary step for analyzing the regulatory mechanism and function of miRNAs. Herein, miTarbase was used to identify the target mRNAs of 61 DE-miRNAs. The DE-miRNAs, with more than five target genes (support type: functional MTI), were selected. Cytoscape software was then used to visualize the regulatory networks of the miRNA–mRNA pairs.⁹ The common mRNAs between the target mRNAs and the DEGs in GSE44270 and GSE92566 were then identified. An online Venn tool (<http://jvenn.toulouse.inra.fr/app/index.html>) was used for Venn diagram analysis.¹⁰

Protein–Protein Interaction (PPI) Network Analysis

A String database (<https://string-db.org/>) (a database of known and predicted protein–protein interactions) was used to construct a PPI network to analyze the interactions between target mRNA and peripheral genes. The nodes and lines in the network diagram represent target genes

and their interactions, respectively, and the color of the lines represents the strength of the interaction.

Gene Ontology (GO) Annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Enrichment Analyses of the DEGs

The Database for Annotation, Visualization, and Integrated Discovery (DAVID) was used for GO annotation and KEGG pathway enrichment analyses of the selected mRNA cluster. GO annotation analysis included biological processes (BPs), cellular components (CCs), molecular functions (MFs). R studio “ggplot” package was used for data visualization.

Tissue-Specific Gene Expression Analysis

An online resource BioGPS (<http://biogps.org>) was used to analyze the tissue-specific expression of the target mRNAs. Herein, a gene was defined as highly tissue-specific if the level of tissue-specific expression was 10 times that of the median. The top three tissues with the highest expression levels were recorded if a gene was expressed more than 10 times in multiple tissues.

Bgee is a database that compares gene expression patterns across a wide range of animal species, generated by integrating multiple data types (RNA-Seq, Affymetrix, in situ hybridization, and EST data). It is based entirely on selected healthy wild-type expression data (eg, no knock-out, no treatment, no disease) to provide a comparable reference for normal gene expression. Thus, Bgee can detect the expression conditions of any single gene, adapted to any data type and species. Bgee version 14.1 includes 29 animals and is available at <https://bgee.org/> and the development pack BgeeDB.

Cell-Specific Gene Expression Analysis

HPA (<http://www.proteinatlas.org/>) is an online database that can be used to detect the expression of target genes in different cells, tissues and organs. The database is based on RNA sequencing (RNA-seq) analysis and immunohistochemical (IHC) data from previous studies.¹¹ Herein, the HPA database was used to analyze the expression of target mRNAs of DE-miRNAs in multiple single cells of the skin. The single-cell RNA sequencing data in the HPA database were obtained from publicly available whole-genome expression data. The site contains all protein-coding genes in 12 cell-type groups and 192 cell-type clusters.¹¹ It enables the user to study the expression of genes in different single-cell types and their expression in different single-cell types. The genes expressed in each cell type can be explored in interactive UMAP plots and bar charts, with links to corresponding immunohistochemical staining in human tissues.¹¹

Sample Collection and Storage

Patients with keloids and healthy individuals were recruited from the Clinic of Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital. Keloids were diagnosed as previously described.¹² Scar tissue from keloid patients and normal skin tissue from the inguinal area of healthy individuals were used for validation tests. Each collected sample was labeled and stored in liquid nitrogen until needed. The basic information of keloid patients and healthy donors is described in Table 1.

Total RNA Extraction and Quantitative RT-PCR

Total RNA was isolated from keloid sample and normal skin sample using TRIzol reagent (Invitrogen). Next, cDNA was

Table 1 General Information of Patients

	Keloid Patients	Normal Control
Number	16	20
Males/females (n)	7/9	4/16
Age (y), mean ± SD	29.3±11.4	29.62±15.22
Surgery/injury history	12	15
History of infectious diseases (HIV, viral hepatitis, etc)	2	4
Hormone therapy history	13	2
Laser treatment history	13	2
SCAR score (n)	11 (4) 10 (2) 9 (4) 8 (6)	N/A
Site of keloid	Lower trunk (1); upper trunk (14); face (1)	N/A

Table 2 Information of Primer Sequences Used for RT-PCR

Gene Symbol	Primer Sequences
miR-30b-5p	Forward: 5'-GGGCTGTAAACATCCTACAC-3'
	Reverse: 5'-GGGCTGTAAACATCCTACA-3
miR-212-3p	Forward: 5'-AGCATCCACGAGCAAGAGAC-3'
	Reverse: 5'-GATGCTACTAGTGTGGCGGG-3'
miR-149-5p	Forward: 5'-CCCTATTCTGTCCACACTCCAGCTGGG-3'
	Reverse: 5'-TGGTGTCTGTGGAGTCG-3'
U6	Forward: 5'-GCTTCGGCAGCACATATACTAAAAT-3'
	Reverse: 5'-CGCTTCACGAATTTGCGTGTCTAT-3'
<i>SIX1</i>	Forward: 5'-AAGGAGAAGTCGAGGGGTGT-3'
	Reverse: 5'-TGCTTGTGGAGGAGGAGTT-3'
<i>CCNA2</i>	Forward: 5'-GGATGGTAGTTTGTAGTCACCAC-3'
	Reverse: 5'-CACGAGGATAGCTCTCATACTGT-3'
<i>FOXMI</i>	Forward: 5'-TGCCAGCAGTCTCTTACCT-3'
	Reverse: 5'-CTACCCACCTTCTGGCAGTC-3'
<i>CCNB1</i>	Forward: 5'-GCATTTCTCTCTCTCA-3'
	Reverse: 5'-CGATGTGGCATACTTGT-3'
<i>RUNX2</i>	Forward: 5'-CACTGGCGGTGCAACAAGA-3'
	Reverse: 5'-ATGACGGTAACACAGTCCCATC-3'
GAPDH	Forward: 5'-GGAGCGAGATCCCTCCAAAT-3'
	Reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3'

synthesized using the PrimeScript RT reagent Kit (Takara Bio Company, Shiga, Japan). After reverse transcription of total RNA, quantitative RT-PCR was conducted to determine the expression of MAIT cells using SYBR Premix Ex Taq (TaKaRa, Dalian, China) on a Light Cycler 480 SYBR Green I Master (Roche Diagnostics, Basel, Switzerland). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the control gene. The 2- $\Delta\Delta C_t$ method was used to determine the gene expression levels. Primer sequences are shown in Table 2. All of the experiments were performed three times in triplicate.

Statistical Analysis

All the data were analyzed using GRAPHPAD PRISM (version 6, GraphPad, La Jolla, CA, USA). Differences between groups were analyzed using Student's *t*-test. The significance was defined at $P < 0.001$ (***), $P < 0.01$ (**), and $P < 0.05$ (*).

Results

Identification of DE-miRNAs

MicroRNA expression profile data of GSE113620 were obtained from the GEO database. A total of 164 DE-miRNAs (91 downregulated and 73 upregulated genes) were found in keloid-prone subjects in baseline vs keloid-prone subjects 42 days after wounding (Figure 1A). A total of 114 DE-miRNAs (38 upregulated and 76 downregulated genes) were found in healthy subjects in baseline vs healthy subjects 42 days after wounding (Figure 1B). Venn diagrams were developed to analyze common genes in different subsets, of which 69 genes were expressed differently only in the keloid-prone subjects in baseline vs keloid-prone subjects 42 days after wounding (Figure 1C). Those 69 DE-miRNAs were selected for subsequent analysis.

Identification of Target mRNAs of DE-miRNAs

The target genes of the above 69 genes were identified in Mirtarbase, the target gene prediction database for miRNAs. Six DE-miRNAs, with more than five target genes (support type: functional MTI), were used to build a network of DE-miRNAs-mRNAs interactions using Cytoscape (Figure 2A). The six DE-miRNAs and their target mRNAs are shown in Table 3 (159 genes are listed, eight target genes overlapped). The 151 target mRNAs were then compared with the DEGs in two microarrays (GSE44270 and GSE92566) to identify the target mRNAs related to keloid. There were six comparison groups in GSE44270 and one in GSE92566 (KK vs NLK, KF vs CF, KK vs CK, KF vs NLF, NLK vs CK, NLF vs CF in GSE44270, and Keloid vs Control in GSE92566). There were no common DEGs in the KF vs NLF group, which is not shown in the figure. Finally, among the 151 target mRNAs of DE-miRNAs, we found seven mRNAs that were differentially expressed in keloid by analyzing DEGs in GSE44270 and GSE92566. *LIF* and *SIX1* were identified in KF vs CF; *CCNA2*, *CCNB1*, and *FOXMI* were identified in KK vs NLK; *DPYSL2* was identified in KK vs CK; *RUNX2* was identified in Keloid vs Control (GSE92566). The final results were expressed as a Venn diagram (Figure 2B). The PPIs were mapped using the logical data from the STRING database to further assess the correlation between the above seven genes (Figure 2C). The network consisted of seven nodes and five edges, and the average local clustering coefficient was

Figure 1 (A) Identification of DE-miRNAs. A total of 164 DE-miRNAs, including 91 downregulated and 73 upregulated genes, were found in keloid-prone subjects in baseline vs keloid-prone subjects 6 weeks after wounding. **(B)** However, 115 DE-miRNAs, including 38 upregulated and 76 downregulated genes, were found in healthy subjects in baseline vs healthy subjects 6 weeks after wounding. **(C)** Venn diagrams were developed to analyze common genes in different subsets, of which 69 genes were expressed differently only in the Keloid 0-Day vs Keloid 42-Day group.

Figure 2 (A) MiRNA–target gene interactions. By searching the miRNA target gene prediction database, we found the target genes of DE-miRNAs. The predictions were verified by mirtarbase. Eventually, we selected six DE-miRNAs, whose target genes (support type: functional MTI) are more than five and build the network of miRNA–mRNA interactions using Cytoscape. Red node indicates the expression of gene is increased in keloid, while green indicates the expression of gene is decreased in keloid. (B) After selecting mRNAs of DE-miRNAs, we compared the above target mRNAs with DEGs in GSE44270 and GSE92566, and selected the overlapping mRNAs for future studies. Finally, we selected seven mRNAs that were DEGs in GSE44270 or GSE92566. (C) We plotted the PPI network diagram of the above seven genes to describe the connections among the seven genes. Moreover, *LIF* and *DPYSL2* genes had no association with the other five genes, hence were abandoned in further study. (D) The connection of three DE-miRNAs and five DE-target mRNAs. Red node indicates the expression of gene is increased in keloid compared with control groups, while green node indicates the expression of gene is decreased in keloid compared with control groups.

Table 3 Target Genes of Identified DE-miRNAs

The miRNA-mRNA Network		
Gene Symbol	Experiments	References (PMID)
Target genes of hsa-miR-181c-5p (Up regulated, log2FC= 1.671, adj P value=0.01)		
NLK	Luciferase reporter assay	19585654
GATA6	Luciferase reporter assay	19585654
CDX2	Luciferase reporter assay	19585654
KRAS	Luciferase reporter assay/qRT-PCR/Western blot	20080834
NOTCH4	Luciferase reporter assay/qRT-PCR/Western blot	20080834
BCL2	Luciferase reporter assay/qRT-PCR/Western blot/	20162574
TRIM2	In situ hybridization/Luciferase reporter assay	21720722
SIRT1	In situ hybridization/Luciferase reporter assay	21720722
BTBD3	In situ hybridization/Luciferase reporter assay	21720722
BMPR2	Luciferase reporter assay	23352489
IL2	Reporter assay; qRT-PCR	21112091
DPYSL2	qRT-PCR/Western blot	23667495
MECP2	qRT-PCR/Western blot	23667495
RAP1B	Immunofluorescence/Luciferase reporter assay/qRT-PCR/Western blot	24573637
PRKCD	Luciferase reporter assay	26629004
PRAP1	qRT-PCR/ELISA/Luciferase reporter assay/Western blot	25554417
MST1	Immunoprecipitation/Luciferase reporter assay/Western blot	26561204
LATS2	Immunoprecipitation/Luciferase reporter assay/Western blot	26561204
SGMS1	Immunoprecipitation/Luciferase reporter assay/Western blot	26561204
SAV1	Immunoprecipitation/Luciferase reporter assay/Western blot	26561204
PTEN	Immunofluorescence/Luciferase reporter assay/Western blot	25695913
ST8SIA4	Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	27527856
NDRG2	Luciferase reporter assay/qRT-PCR/Western blot	27533020
TGFBR1	Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	26682928
TGFBR2	Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	26682928
TGFBRAP1	Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	26682928
IL7	ELISA/Luciferase reporter assay/qRT-PCR	25962782
Target genes of hsa-miR-212-3p (Up regulated, log2FC= 2.56, adj P value <0.001)		
MECP2	Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot/Reporter assay; Western blot; Microarray;	20020497
TJP1	Western blot/Luciferase reporter assay	18162065
PEA15	qRT-PCR/Luciferase reporter assay/Western blot	20388802
PTCH1	Luciferase reporter assay/qRT-PCR/Western blot	22357618
RB1	Luciferase reporter assay/Western blot/Reporter assay; Western blot; qRT-PCR	21329664
KCNJ2	Immunoblot/Luciferase reporter assay/qRT-PCR	22880819
CCNA2	Western blot; qRT-PCR	21329664
CCNB1	Western blot; qRT-PCR	21329664
RBP2	Luciferase reporter assay/qRT-PCR/Western blot	23922798
MYC	Luciferase reporter assay/qRT-PCR/Western blot	21053104
SOD2	Luciferase reporter assay	23583431
ACHE	In situ hybridization/Luciferase reporter assay/qRT-PCR/Western blot	23974008
IRAK4	Luciferase reporter assay	23264652
PXN	Luciferase reporter assay/qRT-PCR/Western blot	26693054
RFXAP	Luciferase reporter assay/qRT-PCR/Western blot	26337469
SOX4	Immunoprecipitation/Luciferase reporter assay/qRT-PCR/Western blot	26377202
SOX11	Luciferase reporter assay	25766675

(Continued)

Table 3 (Continued).

The miRNA-mRNA Network		
Gene Symbol	Experiments	References (PMID)
<i>ABCG2</i>	Luciferase reporter assay	25766675
<i>ADCY1</i>	Luciferase reporter assay	25766675
<i>SGK3</i>	Luciferase reporter assay/qRT-PCR/Western blot	25720694
<i>SMAD2</i>	GFP reporter assay/qRT-PCR/Western blot	25988335
Target genes of hsa-miR-199a-5p (Up regulated, log2FC= 1.11, adj P value <0.001)		
<i>IKBKB</i>	Reporter assay/Western blot/GFP reporter assay/Luciferase reporter assay/qRT-PCR	18408758
<i>LIF</i>	ELISA/Luciferase reporter assay	19011087
<i>JUNB</i>	Luciferase reporter assay/Microarray/qRT-PCR/Western blot	25938468
<i>DDR1</i>	Luciferase reporter assay/qRT-PCR/Western blot	20799954
<i>EDN1</i>	Luciferase reporter assay	19783678
<i>MAP3K11</i>	Luciferase reporter assay/qRT-PCR/Western blot	21048306
<i>HIF1A</i>	Luciferase reporter assay/qRT-PCR/Western blot	21847633
<i>SMARCA2</i>	Luciferase reporter assay/qRT-PCR/Western blot	21189327
<i>CD44</i>	Luciferase reporter assay	22498306
<i>TMEM54</i>	Immunoblot/In situ hybridization/Luciferase reporter assay/Northern blot/qRT-PCR	22903020
<i>SMAD4</i>	Luciferase reporter assay	22821565
<i>SULT1E1</i>	Luciferase reporter assay	23060436
<i>GPR78</i>	Luciferase reporter assay	23085757
<i>ERBB2</i>	Western blot	23437196
<i>UNG</i>	Luciferase reporter assay	23228472
<i>CAVI</i>	Luciferase reporter assay	23459460
<i>SIRT1</i>	qRT-PCR/Western blot	23760629
<i>HSPA5</i>	Luciferase reporter assay/qRT-PCR/Western blot	23598416
<i>ATF6</i>	Luciferase reporter assay/qRT-PCR/Western blot	23598416
<i>ERN1</i>	Luciferase reporter assay/qRT-PCR/Western blot	23598416
<i>KL</i>	EMSA/FACS/Flow/GFP reporter assay/Gluc reporter assay/GUS reporter assay/HITS-CLIP/Immunoblot/Immunocytochemistry/Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot/In situ hybridization	24655788
<i>APOE</i>	ELISA/Luciferase reporter assay/Microarray	23142051
<i>DNAJA4</i>	ELISA/Luciferase reporter assay/Microarray	23142051
<i>ERBB3</i>	Immunoblot/Immunohistochemistry/Luciferase reporter assay/qRT-PCR	23146892
<i>CDH1</i>	Immunofluorescence/Immunohistochemistry/Immunoprecipitation/Luciferase reporter assay/Microarray/qRT-PCR/ Western blot	25080937
<i>PTGS2</i>	Luciferase reporter assay/Western blot	24413338
<i>LIN7A</i>	Luciferase reporter assay	23201090
<i>ARHGAP12</i>	Luciferase reporter assay	23201090
<i>CTSC</i>	Luciferase reporter assay	23201090
<i>RND1</i>	Luciferase reporter assay	23201090
<i>NECTIN1</i>	Luciferase reporter assay	23201090
<i>DRAM1</i>	Luciferase reporter assay/Western blot	23337876
<i>BECN1</i>	Luciferase reporter assay/Western blot	23337876
<i>MAFB</i>	Luciferase reporter assay/Western blot	24391856
<i>WNK1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24299514
<i>NFKB1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24299514
<i>ACVR1B</i>	Immunoprecipitation/qRT-PCR/Western blot/Luciferase reporter assay	25258381
<i>VEGFA</i>	Luciferase reporter assay	24155090
<i>CDH2</i>	Luciferase reporter assay/Western blot	25041364

(Continued)

Table 3 (Continued).

The miRNA-mRNA Network		
Gene Symbol	Experiments	References (PMID)
<i>SNAIL</i>	Luciferase reporter assay/Western blot	25041364
<i>GSK3B</i>	ChIP-seq/FACS/Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot	23764775
<i>FZD4</i>	ChIP-seq/FACS/Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot	23764775
<i>WNT2</i>	ChIP-seq/FACS/Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot	23764775
<i>JAG1</i>	ChIP-seq/FACS/Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot	23764775
<i>HK2</i>	Luciferase reporter assay/qRT-PCR/Western blot	26054020
<i>KRAS</i>	qRT-PCR/Western blot	26027911
<i>SMAD3</i>	Luciferase reporter assay	27038547
<i>ETS1</i>	Luciferase reporter assay	27094578
<i>CCR7</i>	Luciferase reporter assay/qRT-PCR	27814720
<i>PDE4D</i>	Luciferase reporter assay	26344589
<i>TGFB2</i>	Luciferase reporter assay/qRT-PCR	27842518
<i>PIK3CD</i>	Luciferase reporter assay/qRT-PCR	27842518
<i>SETD2</i>	Luciferase reporter assay	26191163
<i>LDLR</i>	Luciferase reporter assay/qRT-PCR/Western blot	26163491
<i>CLTC</i>	Luciferase reporter assay/qRT-PCR/Western blot	26163491
<i>RAB21</i>	Luciferase reporter assay/qRT-PCR/Western blot	26163491
<i>OSCP1</i>	Luciferase reporter assay/Microarray/qRT-PCR/Western blot	26781989
<i>PIAS3</i>	Luciferase reporter assay/qRT-PCR/Western blot	28120918
<i>PSMD9</i>	Luciferase reporter assay/qRT-PCR/Western blot	28120918
<i>CDKN1C</i>	Luciferase reporter assay	25588980
<i>ITGA3</i>	Luciferase reporter assay/qRT-PCR/Western blot	28324890
<i>FZD6</i>	Immunohistochemistry/LacZ reporter assay/qRT-PCR/Western blot	25772759
<i>MAP4K3</i>	Luciferase reporter assay/qRT-PCR/Western blot	28099144
<i>TGFBRI</i>	Luciferase reporter assay/Microarray/qRT-PCR/Western blot	25938468
<i>SLC27A1</i>	Luciferase reporter assay/Microarray/qRT-PCR/Western blot	27562723
Target genes of hsa-miR-339-5p (Up regulated, log2FC= 1.61, adj P value=0.03)		
<i>BCL6</i>	Immunohistochemistry/Luciferase reporter assay/Western blot	24917186
<i>PTP4A1</i>	Luciferase reporter assay/qRT-PCR/Western blot	23696794
<i>BACE1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24352696
<i>NOVA1</i>	Luciferase reporter assay/qRT-PCR/Western blot	26391641
<i>MDM2</i>	Luciferase reporter assay	24882579
Target genes of hsa-miR-30b-5p (Up regulated, log2FC= -1.12, adj P value<0.001)		
<i>CCNE2</i>	Luciferase reporter assay/qRT-PCR	22384020
<i>SMAD1</i>	Luciferase reporter assay/Western blot	22253433
<i>BCL6</i>	Luciferase reporter assay/qRT-PCR/Western blot	22387553
<i>SOCS1</i>	Luciferase reporter assay/qRT-PCR/Western blot	22387553
<i>SNAIL</i>	Luciferase reporter assay/qRT-PCR/Western blot	21633953
<i>CAT</i>	Luciferase reporter assay/qRT-PCR/Western blot	22880027
<i>ATG12</i>	GFP reporter assay/Luciferase reporter assay/qRT-PCR/Western blot	22647547
<i>RUNX2</i>	Microarray/qRT-PCR/Luciferase reporter assay	23316327
<i>DNMT1</i>	qRT-PCR/Western blot	24913034

(Continued)

Table 3 (Continued).

The miRNA–mRNA Network		
Gene Symbol	Experiments	References (PMID)
<i>ERG</i>	Luciferase reporter assay/Microarray/qRT-PCR/Western blot	23728339
<i>BECN1</i>	GFP reporter assay/Luciferase reporter assay/qRT-PCR/Western blot	22647547
<i>SERPINE1</i>	GFP reporter assay/Luciferase reporter assay/Northern blot/qRT-PCR/Western blot	25170877
<i>DLL4</i>	In situ hybridization/Luciferase reporter assay/qRT-PCR/Western blot	23086751
<i>SIX1</i>	Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	24593661
<i>BCL9</i>	Immunofluorescence/Immunohistochemistry/In situ hybridization/Luciferase reporter assay/qRT-PCR/Western blot	24599134
<i>NOTCH1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24029422
<i>MBNL1</i>	Luciferase reporter assay	26840300
<i>MBNL2</i>	Luciferase reporter assay	26840300
<i>PDGFRB</i>	Luciferase reporter assay/qRT-PCR/Western blot	23893664
<i>TP53</i>	Luciferase reporter assay/qRT-PCR/Western blot	24029422
<i>BCL2</i>	Luciferase reporter assay	24178239
<i>MBNL3</i>	Luciferase reporter assay	26840300
<i>EIF2S1</i>	Luciferase reporter assay	26898246
<i>EIF5A2</i>	Luciferase reporter assay/qRT-PCR/Western blot	26309359
<i>RASAL2</i>	Luciferase reporter assay	25547110
<i>CTHRC1</i>	Luciferase reporter assay/Western blot/qRT-PCR	26388700
<i>HOXA1</i>	Luciferase reporter assay/qRT-PCR/Western blot	28189678
Target genes of hsa-miR-149-5p (Down regulated, log2FC= −1.44, adj P value <0.001)		
<i>SP1</i>	Luciferase reporter assay	22821729
<i>FOXMI</i>	Luciferase reporter assay/Western blot	23762558
<i>ZBTB2</i>	Immunohistochemistry/Luciferase reporter assay/qRT-PCR/Western blot	23144691
<i>GIT1</i>	Immunofluorescence/Immunohistochemistry/Luciferase reporter assay/Microarray/qRT-PCR/Western blot	24608434
<i>FGFR1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24463821
<i>GPC1</i>	Luciferase reporter assay/qRT-PCR/Western blot	24463821
<i>MYD88</i>	ELISA/qRT-PCR/Western blot	24375488
<i>IL6</i>	ELISA/Luciferase reporter assay/qRT-PCR/Western blot	25916550
<i>PTGER2</i>	ELISA/Luciferase reporter assay/qRT-PCR/Western blot	25916550
<i>BBC3</i>	Immunofluorescence/Luciferase reporter assay/Northern blot/qRT-PCR/Western blot	23873935
<i>FGF21</i>	Western blot	27061435
<i>MTHFR</i>	Immunoblot/Luciferase reporter assay/qRT-PCR/Western blot	28045918
<i>FASLG</i>	Luciferase reporter assay/qRT-PCR/Western blot	28013316
<i>PPM1F</i>	Luciferase reporter assay/Western blot	26498692

0.524. The PPI network showed that *SIX1*, *CCNA2*, *CCNB1*, *FOXMI*, and *RUNX2* formed a gene cluster regulated by three DE-miRNAs (Figure 2D). Those five genes were used as DE-target mRNAs in the subsequent analysis.

Protein Interaction Network Construction

In order to further understand the biological interaction of *SIX1*, *CCNA2*, *CCNB1*, *FOXMI*, and *RUNX2*, we constructed

an expanded PPI network. The network had 55 nodes, 52 genes, and 951 edges, with an average local clustering coefficient of 0.836 (Figure 3). These 52 genes represent a gene cluster based on *SIX1*, *CCNA2*, *CCNB1*, *FOXMI*, and *RUNX2*.

Expression Analyses of Target mRNAs of DE-miRNAs

Next, in order to investigate the biological role of this gene cluster in keloids, we performed gene enrichment analysis.

Figure 3 A PPI network with 55 nodes, 52 genes, and 951 edges was constructed based on five DE-miRNAs' target mRNAs (*SIX1*, *CCNA2*, *CCNB1*, *FOXM1*, and *RUNX2*).

DAVID online tool was used for GO annotation and KEGG pathway analyses. The top five items in each enrichment analysis are shown in Figure 4A. For the purpose of validating the expression of those five genes in keloid, we further analyzed the expression of target genes in the single-cell type clusters identified in skin, and the data was visualized by a bar chart (Figure 4B). The single-cell RNA sequencing (scRNAseq) data were obtained from the HPA database. The results showed that the expression level of *CCNA2*, *CCNB1*, *RUNX2*, and *FOXM1* was relatively higher in fibroblast c-9 cell cluster (fibroblast mesenchymal cells) than in other cell clusters in the skin. *SIX1* expression increased in the fibroblast c-3 cell cluster, which also identified as fibroblast mesenchymal cells. The expression profile of the five genes in a specific tissue or organ system was also identified using BioGPS. The results showed that *CCNA2* expression was highest in B lymphoblast, followed by CD34 and

CD105+ endothelial cells. Similarly, *CCNB1* expression was highest in B lymphoblast, followed by CD71+ early erythroid and CD105+ endothelial cells. *FOXM1* expression was highest in Burkitt's lymphoma, followed by CD71+ early erythroid and B lymphoblast. *SIX1* and *RUNX2* were not specifically expressed in tissues. Next, we tried to analyze the expression and existence of these five genes in healthy human tissues and organs through Bgee database. The data were expressed in a bar chart (Figure 4C). We found that compared with normal subcutaneous adipose tissue, except *SIX1*, the expression difference of other genes in subcutaneous adipose tissue and skin was not obvious. This suggests that the expression differences of *CCNA2*, *CCNB1*, *RUNX2*, and *FOXM1* in tissue adjacent to the skin are not obvious in healthy donors. Therefore, we suspect that abnormal expression of *CCNA2*, *CCNB1*, *RUNX2*, and *FOXM1* may be associated with keloid formation.

Figure 4 (A) The enrichment analysis of the 52 genes mentioned in Figure 3 was analyzed to study the biological function of the gene cluster based on five DE-miRNAs' target mRNAs. (B) We further analyzed the expression of five target genes in the single-cell-type clusters identified in the skin to analyze the expression of those five mRNAs in different cell types. (C) Expression and existence of these five genes in different healthy human skin tissues was analyzed using Bgee database.

Validation of the Identified miRNAs/mRNAs

After we screened a gene cluster containing five mRNAs and three miRNAs through the above steps, for further confirmation, the expression level of five genes (*SIX1*, *CCNA2*, *CCNB1*, *FOXM1*, *RUNX2*) and three miRNAs (miR-30b-5p, miR-212-3p, miR-149-5p) in keloid tissue and normal skin was analyzed by using RT-PCR. According to our results, we found that the expression of miR-30b-5p, miR-212-3p, *CCNB1*, *RUNX2* and *SIX1* in keloid was significantly higher than that in healthy donors, and the expression of miR-149-5p in keloid was significantly lower than that in healthy donors, and the difference was statistically significant (Figure 5).

Discussion

Herein, this study aimed to identify biomarkers for keloid and a cluster containing five genes (*SIX1*, *CCNA2*, *CCNB1*, *FOXM1*, *RUNX2*) controlled by three miRNAs (miR-30b-5p, miR-212-3p, miR-149-5p) were determined. In this study, we identified a novel pathway, miR-149-5p-*FOXM1*. miR-149-5p is overexpressed in multiple cancers, such as breast cancer, lung cancer, kidney cancer, and bladder cancer. By regulating il-6/STAT3 pathway, miR-149-5p thus affects the proliferation and metabolism of tumor cells.^{13–17} However, there has been no research report on the correlation between the expression of miR-149-5p and keloid so far. This is the first study to reveal the association between miR-149-5p and keloid. *FOXM1* (Forkhead Box M1) is involved in cell proliferation. *FOXM1* protein is phosphorylated in the M phase of the cell cycle, thus regulating the expression of several cell cycle genes, such as cyclin B1 and cyclin D1. Consistent with previous studies, enrichment analysis in this study demonstrated that the PPI network containing *FOXM1* is mainly associated with the cell cycle. Previous research showed that *FOXM1* knockout inhibits keloid fibroblast activation and extracellular matrix production by affecting the activation of the TGF- β 1/Smad pathway.¹⁸ Another research also found that *FOXM1* promotes keloid progression by participating in the HOXA11-AS-miR-205-5p-*FOXM1* pathway.¹⁹ Therefore, the novel pathway miR-149-5p-*FOXM1* could provide the underlying mechanism of keloid.

Our results indicate that miR-212-3p can promote keloid formation by regulating *CCNA2* or *CCNB1*. miR-212-3p regulates cancer tumorigenesis, differentiation, proliferation, and survival by inhibiting major genes,

including *SGK3*, *SOX4*, *SOX11*, *SOX5*.^{20–24} There are currently no reports in literature for the function of miR-212-3p on keloid. Unlike miR-212-3p, *CCNB1* and *CCNB2* alterations may contribute to keloid formation via dysregulation of cell cycle and p53 signaling pathways.²⁵ Furthermore, another research showed that *CCNB1* expression might be related to 5-fluorouracil treatment in keloid fibroblasts, suggesting that further study of *CCNB1* may lead to new breakthroughs in the treatment of keloids.²⁶ In our study, we not only confirmed the abnormal expression of miR-212-3p and *CCNB1* in keloid compared with normal skin but also found that the expression differences of *CCNB1* and *CCNA2* in normal tissue adjacent to the skin are not obvious in healthy people. Therefore, we suspect that abnormal expression of miR-212-3p and *CCNB1* may play a role in keloid formation. Considering strong biological connections between *CCNB1*, *CCNB2*, and *CCNA2*, they may act together to influence the keloid formation via regulating fibroblast cell cycle, and miR-212-3p may act as a key regulatory node in this process.

Our findings suggest that the miR-30b-5p-*SIX1*/*RUNX2* pathway may be associated with keloid. Various studies have shown that miR-30b-5p is associated with tumorigenesis and tumor metastasis.²⁷ Previous studies have illustrated that miR-30b-5p promotes keloid fibroblast proliferation by participating in DLEU2-miR-30a-5p/miR-30b-5p pathway.²⁸ *RUNX2* is a member of the *RUNX* family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. Consistent with our study, previous studies have indicated that keloid is related to the expression of *RUNX2*.²⁹ Specifically, *RUNX2* siRNA therapy may reverse pathological keloid phenotypes by inhibiting PI3K/AKT signaling,³⁰ suggesting that *RUNX2* is a promising biomarker for keloid therapy. Besides, previous studies have shown that miR-194-3p can directly regulate *RUNX2*.³¹ Herein, *RUNX2* was associated with miR-30b-5p, providing a new regulatory target for *RUNX2* regulation in keloid. The *SIX1* gene located on chromosome 14 has been associated with limb development, and it encodes a homeobox protein called SIX protein. The autosomal dominant deafness type 23 and branchiootoc syndrome type 3 are associated with *SIX1*. However, no study has comprehensively demonstrated the correlation between *SIX1* and keloid. In this study, *SIX1* was differentially expressed in KF vs CF, suggesting that *SIX1* may promote the formation of the keratinocyte layer of keloid. The

Figure 5 The expression of DE-miRNAs and DE-target mRNAs was validated using RT-PCR. The $2^{-\Delta\Delta Ct}$ method was used to determine the gene expression levels. Differences between groups were analyzed using Student's *t*-test. The significance was defined at $P < 0.001$ (***), $P < 0.01$ (**), and $P < 0.05$ (*).

abnormal expression of miR-30b-5p, *RUNX2* and *SIX1* in keloid compared with normal skin was validated. In addition, we found that there was no obvious difference in *RUNX2* expression between normal skin tissue and adjacent adipose tissue, suggesting that the differential expression of *RUNX2* and *SIX1* in keloid may be related to the pathogenesis of keloid, which may be regulated by Mir-30b-5p.

However, this study has several limitations. First, the small number of samples obtained from GSE113620 introduced bias during the analysis of DE-miRNAs. Therefore, more chip data are necessary for statistical analysis to verify the experimental results. Moreover, the functional and molecular mechanisms of genes are complex, and predictions based on bioinformatics alone require cell and animal experiments. Lastly, in the three RNA-seq analysis (GSE113620, GSE44270, GSE92566) we studied, the source of sample was different. In GSE44270, sample were excised from patients undergoing surgery, and then primary cells of skin and scar tissue were cultured for further microarray analysis. However, in GSE113620 and GSE92566, skin and scar tissues were excised and preserved with RNAlater, and subsequently the sample tissue was used for RNA extraction and RNA-seq analysis. We believe that the formation of keloid is closely related to its environment, such as tension and inflammation. Therefore, after the removal of external factors, the gene expression in cultured primary cell may be different from that of tissue sample. That is to say, the results of this study need to be further verified with appropriate sample.

Conclusion

In our study, a PPI network containing 52 genes was constructed based on five target mRNAs of DE-miRNAs. Gene enrichment analysis showed that the biological function of this gene cluster is mainly associated with the cell cycle. Therefore, the three DE-miRNAs may influence keloid proliferation by affecting the gene functional groups centered on *CCNA2*, *CCNB1*, *SIX1*, *RUNX2*, and *FOXMI*. This study may provide reliable biomarkers for accurate diagnosis and individualized keloid treatment, and further clinical application.

Data Sharing Statement

All data generated or analyzed during this study are included in this published article.

Ethics Statement

This study was approved by the ethical committee of Shanghai Ninth People's Hospital and consent was received from the study participants, and that the guidelines outlined in the Declaration of Helsinki were followed. All patients were informed of the purpose of this study and signed informed consent before sample collection.

Patient Consent for Publication

There were no patients enrolled in this study.

Funding

This study was funded by the National Natural Science Foundation of China (No. 81772098, 82002064), Shanghai Sailing Program (No. 20YF1422700), and Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (No. 20152227). The funders of the study had no role in the design or conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript, and/or decision to submit the manuscript for publication.

Disclosure

The authors declare that they have no competing interests.

References

1. Shin JY, Kim JS. Could 5-fluorouracil or triamcinolone be an effective treatment option for keloid after surgical excision? A meta-analysis. *J Oral Maxillofac Surg.* 2016;74(5):1055–1060. doi:10.1016/j.joms.2015.10.002
2. Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. *J Invest Dermatol.* 2008;128(5):1298–1310. doi:10.1038/sj.jid.5701149
3. Zhong L, Bian L, Lyu J, et al. Identification and integrated analysis of microRNA expression profiles in keloid. *J Cosmet Dermatol.* 2018;17(5):917–924. doi:10.1111/jocd.12706
4. Pang Q, Wang Y, Xu M, et al. MicroRNA-152-5p inhibits proliferation and migration and promotes apoptosis by regulating expression of Smad3 in human keloid fibroblasts. *BMB Rep.* 2019;52(3):202–207. doi:10.5483/BMBRep.2019.52.3.278
5. Shi K, Qiu X, Zheng W, Yan D, Peng W. MiR-203 regulates keloid fibroblast proliferation, invasion, and extracellular matrix expression by targeting EGR1 and FGF2. *Biomed Pharmacother.* 2018;108:1282–1288. doi:10.1016/j.biopha.2018.09.152
6. Nuerzhati Y, Dong R, Song Z, Zheng S. Role of the long non-coding RNA-Annexin A2 pseudogene 3/Annexin A2 signaling pathway in biliary atresia-associated hepatic injury. *Int J Mol Med.* 2019;43(2):739–748. doi:10.3892/ijmm.2018.4023
7. Tang Z, Ding J, Zhai X, Jing M, Guan Z, Li Y. MicroRNA-21 may be involved in the therapeutic effects of galla chinensis ointment on keloid. *J Int Med Res.* 2020;48(3):300060520909602. doi:10.1177/0300060520909602

8. Tao J, Cong H, Wang H, et al. MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1. *Biochem Biophys Res Commun.* 2018;503(2):1092–1097. doi:10.1016/j.bbrc.2018.06.121
9. Wang Q, Liu B, Wang Y, Bai B, Yu T, Chu XM. The biomarkers of key miRNAs and target genes associated with acute myocardial infarction. *PeerJ.* 2020;8:e9129. doi:10.7717/peerj.9129
10. Bardou P, Mariette J, Escudé F, Djemiel C, Klopp C. jvenn: an interactive venn diagram viewer. *BMC Bioinform.* 2014;15(1):1–7. doi:10.1186/1471-2105-15-293
11. Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. *Protein Sci.* 2018;27(1):233–244. doi:10.1002/pro.3307
12. Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. *Burns.* 2014;40(7):1255–1266. doi:10.1016/j.burns.2014.02.011
13. Chen P, Yao Y, Yang N, Gong L, Kong Y, Wu A. Circular RNA circCTNNA1 promotes colorectal cancer progression by sponging miR-149-5p and regulating FOXM1 expression. *Cell Death Dis.* 2020;11(7):557. doi:10.1038/s41419-020-02757-7
14. Chen S, Chen D, Yang H, Wang X, Wang J, Xu C. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis. *BMC Gastroenterol.* 2020;20(1):39. doi:10.1186/s12876-020-01189-z
15. Xu Z, Tie X, Li N, Yi Z, Shen F, Zhang Y. Circular RNA hsa_circ_0000654 promotes esophageal squamous cell carcinoma progression by regulating the miR-149-5p/IL-6/STAT3 pathway. *IUBMB Life.* 2020;72(3):426–439. doi:10.1002/iub.2202
16. Ye X, Chen X. miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma. *Oncol Lett.* 2019;17(1):372–378. doi:10.3892/ol.2018.9628
17. Zhou Z, Zhang S, Xiong Y. Long noncoding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-149-5p and regulating FOXM1 expression. *Cancer Cell Int.* 2020;20(1):348. doi:10.1186/s12935-020-01432-3
18. Zhang Y, Cheng C, Wang S, Xu M, Zhang D, Zeng W. Knockdown of FOXM1 inhibits activation of keloid fibroblasts and extracellular matrix production via inhibition of TGF- β 1/Smad pathway. *Life Sci.* 2019;232:116637. doi:10.1016/j.lfs.2019.116637
19. Su X, Ma Y, Wang Q, Gao Y. LncRNA HOXA11-AS aggravates keloid progression by the regulation of HOXA11-AS-miR-205-5p-FOXM1 pathway. *J Surg Res.* 2021;259:284–295. doi:10.1016/j.jss.2020.09.035
20. Haenisch S, Zhao Y, Chhibber A, et al. SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. *Neurobiol Dis.* 2015;77:127–140. doi:10.1016/j.nbd.2015.02.025
21. Ju C, Zhou R, Sun J, et al. LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis. *Cancer Cell Int.* 2018;18:141. doi:10.1186/s12935-018-0641-9
22. Liu H, Li C, Shen C, et al. MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. *J Neurooncol.* 2015;122(3):431–439. doi:10.1007/s11060-015-1736-y
23. Wu Z, Yu B, Jiang L. MiR-212-3p mediates apoptosis and invasion of esophageal squamous cell carcinoma through inhibition of the wnt/ β -catenin signaling pathway by targeting SOX4. *J Thorac Dis.* 2020;12(8):4357–4367. doi:10.21037/jtd-20-2558
24. Liu Y, Zhang XL, Li XF, Tang YC, Zhao X. miR-212-3p reduced proliferation, and promoted apoptosis of fibroblast-like synoviocytes via down-regulating SOX5 in rheumatoid arthritis. *Eur Rev Med Pharmacol Sci.* 2018;22(2):461–471. doi:10.26355/eurev_201801_14196
25. Wang H, Quan L, Liang J, et al. Gene expression profiling analysis of keloids with and without hydrocortisone treatment. *Exp Ther Med.* 2017;14(6):5283–5288. doi:10.3892/etm.2017.5263
26. Huang L, Wong YP, Cai YJ, Lung I, Leung CS, Burd A. Low-dose 5-fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. *Br J Dermatol.* 2010;163(6):1181–1185. doi:10.1111/j.1365-2133.2010.09939.x
27. Xu J, Lv H, Zhang B, et al. miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. *J Thorac Dis.* 2019;11(7):3015–3029. doi:10.21037/jtd.2019.07.50
28. Deng Y, Xu Y, Xu S, et al. Secondary data mining of GEO database for long non-coding RNA and competing endogenous RNA network in keloid-prone individuals. *Aging (Albany NY).* 2020;12(24):25076–25089. doi:10.18632/aging.104054
29. Fuentes-Duculan J, Bonifacio KM, Suárez-Fariñas M, et al. Aberrant connective tissue differentiation towards cartilage and bone underlies human keloids in African Americans. *Exp Dermatol.* 2017;26(8):721–727. doi:10.1111/exd.13271
30. Lv W, Wu M, Ren Y, et al. Treatment of keloids through runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway. *Mol Med Rep.* 2021;23(1):1
31. Xu Z, Guo B, Chang P, Hui Q, Li W, Tao K. The differential expression of miRNAs and a Preliminary Study on the Mechanism of miR-194-3p in Keloids. *Biomed Res Int.* 2019;2019:8214923. doi:10.1155/2019/8214923

International Journal of General Medicine

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>

Dovepress